

Economics of preventing premature mortality and impaired cognitive development in children through home-fortification: A health policy perspective

Waseem Sharieff

University of Toronto and McMaster University

Stanley H. Zlotkin, Wendy J. Ungar, Brian Feldman

The Hospital for Sick Children and University of Toronto

Murray D. Krahn, George Tomlinson

Toronto General Hospital and University of Toronto

Background: Home-fortification is a new strategy of adding micronutrients including zinc and iron to home-made foods. Zinc supplementation may prevent morbidity and mortality related to diarrheal illnesses, and iron supplementation may improve cognitive development, in children.

Objectives: To project clinical and economic effects of home-fortification in children in an urban slum of Karachi, Pakistan.

Methods: This is a cost benefit analysis of 5,000 simulated male and female infants (6–12 months) assigned to micronutrients or placebo for 4 months and followed for 55 years. We linked the effect of zinc on longitudinal prevalence of diarrhea to mortality, and the effect of iron on hemoglobin to IQ scores and lifetime earnings. Cost estimates were based on volumes of resource utilization from the Pakistan Sprinkles Diarrhea study. Main outcome was incremental benefit defined as the gain in lifetime earnings after accounting for the incremental costs of micronutrients over placebo (societal perspective).

Results: Our model projected that the reduction in diarrhea and improvement in hemoglobin concentrations through home-fortification was associated with reduced child mortality, higher IQ scores, and higher earnings. The present value of incremental benefit was \$106 (95 percent probability interval = \$17 to \$193) U.S. dollars, which corresponds to \$464.79 (\$74.54 to \$846.27) international dollars using a purchasing power parity exchange rate.

Conclusions: Home-fortification appears to improve clinical outcomes at a reasonable cost, and may actually be cost beneficial when lifetime earnings are considered.

Keywords: Markov model, Monte Carlo simulation, Diarrhea, Iron deficiency, Micronutrients, Cost benefit, Cost effectiveness, Sprinkles

W. Sharieff conceived the study, acquired the data, developed the model, analyzed the results, and wrote the first draft of the paper. S. Zlotkin, B. Feldman, W. Ungar, M. Krahn, and G. Tomlinson critically reviewed the paper for important intellectual contents. G. Tomlinson participated in writing SAS codes. All researchers contributed to the preparation of and approved the paper. The study was supported in part by grants from Canadian Institutes of Health Research, HJ Heinz Foundation, and Institut Rosell Lallemand. The sponsors had no role in study design, data collection, data analysis, data interpretation, or in writing the paper. S. Zlotkin owns the intellectual property rights to micronutrient Sprinkles™. Any profit generated from licensing agreements for the production of Sprinkles is donated to the Hospital for Sick Children Foundation. There are no other “competing interests.”

Zinc and iron deficiencies are common among young children in developing countries and are associated with a high incidence and prevalence of diarrhea, febrile illnesses (including acute respiratory infections), and iron deficiency anemia. Diarrhea-related illnesses are the leading cause of mortality in these children (4;11;38). According to current estimates, 1.6 million children annually die due to diarrhea (17). Iron deficiency anemia may impair cognitive development (18;37). Thus, as adults they may participate less in the workforce and also have lower-paying jobs. Therefore, the net impact of premature mortality and impaired cognitive development is loss of future earnings. This calls for preventative nutritional programs for young children that includes both zinc and iron—improvement in IQ scores by means of iron supplementation would be futile if the child dies of diarrhea, and so would be improvement in life expectancy by means of zinc supplementation if the child attains low IQ.

Sprinkles is a new approach to the prevention of micronutrient deficiencies through fortification of home-made complementary foods (known as “home-fortification”) (27). It contains micronutrients including zinc and iron which are bioavailable (34;39), and effective against diarrhea and febrile illnesses (30), and anemia (40). An economic evaluation from a health care system perspective based on independent effects of zinc on diarrhea, and of iron on IQ scores concluded that Sprinkles were cost-effective (31). A computer simulation model has also been developed that accurately predicts hemoglobin and serum ferritin concentrations in children given iron supplementation (32).

Using data from the Pakistan Sprinkles Diarrhoea study (PSDS) (30), we modified the model to compute rates of diarrhea and febrile days in children, in addition to their hemoglobin values. Thereupon, we carried out a probabilistic cost benefit analysis of home-fortification with Sprinkles from a broad societal perspective, on the basis of the combined impact of zinc and iron on lifetime earnings.

METHODS

Participants and Comparisons

Study participants represented a child population in an urban slum of Karachi, Pakistan. In Pakistan, the prevalence of zinc deficiency is around 38 percent (5), and the prevalence of iron deficiency anemia is around 70 percent (21). The mortality rate in children under 5 years of age is 125 per 1,000 live births. Life expectancy at birth is 62 years and, the per capita gross domestic product (GDP) is \$417 (9). In the current study, we simulated a cohort of 5,000 male and female 6- to 12-month-old children who (at baseline) had a recent history of diarrhea—a population at moderate risk of mortality from diarrhea-related illnesses (2). We assigned these individuals to daily supplements of Sprinkles or placebo administered over 4 months for a total of sixty supplements per individual to compare the mean costs and clinical outcomes in the two groups.

Type of Evaluation and Perspective

Using a human capital approach, we performed a cost benefit analysis from a societal perspective in which incremental benefit was expressed as the gain in lifetime earnings in the Sprinkles group relative to placebo, after accounting for the cost incurred in the two groups (12;15). We included both direct medical costs and time costs incurred in the first year from baseline.

Resource Data and Assumptions

We used data from PSDS to specify sociodemographic and baseline biochemical characteristics of the simulated individuals in this study and to model the effect of Sprinkles on hemoglobin, longitudinal prevalence of diarrhea (percentage days of diarrhea out of observed child-days), febrile child-days, and drug utilization in relation to placebo. For outcomes not directly measured in PSDS, we made assumptions based on observations in other studies.

The key assumption was that, in zinc- and iron-deficient populations, micronutrient supplementation in children, through the immunopotentiating effects of zinc would reduce child mortality from diarrhea-related illnesses (29), and through the neurocognitive effects of iron would enhance work productivity in adult life (20). Underlying assumptions were as follows: (i) a 5 percent absolute increase in longitudinal prevalence of diarrhea is associated with a 17 percent increased risk of mortality (conversely a 5 percent absolute reduction would reduce mortality risk by 15 percent) (22); (ii) a 10 g/L increment in hemoglobin concentration at 9 months of age is associated with a 1.75 point rise in IQ (Wechsler intelligence test) at 5 years of age (23); (iii) the mean difference in IQ scores between treated and untreated groups would persist over lifetime (8); and (iv) a one-point increment in IQ is associated with a 1.1 percent increment in wages (log scale) (1;26). In addition, we assumed that (v) the effect of zinc on longitudinal prevalence of diarrhea would be confined to the period of supplementation (4 months); (vi) postintervention, individuals would have the same life expectancy as of the Pakistani population; (vii) individuals would join work force at 18 years of age and retire from work at 55 years of age; and (viii) the work participation and wage rates would remain constant over time (although individuals may be in or out of the work force). We have schematically presented the key assumptions in Figure 1.

Costs

We identified cost items as Sprinkles sachets, oral rehydration therapy (ORT) sachets, over-the-counter (OTC) drugs, antibiotics, physician fees, and hospital charges, where applicable.

The unit price for Sprinkles sachets (including distribution and overhead) was estimated at \$0.02 (or \$0.08 international dollars) (40). Multiplying this unit price by the volume of resource utilization, which in this study was fixed




Figure 1. Schematic presentation of the key assumptions.

at sixty sachets per child, we calculated that the cost per child for Sprinkles was \$1.2 (or \$5.25 international dollars). Similarly, we obtained unit prices for other items listed above directly from local sources. We multiplied these unit prices by the resource volumes, which in this study were simulated using raw data from PSDS. However, PSDS did not have data on resource volumes for physician fees and hospitalization. Thus, we obtained a range of values for these items from local sources and simulated their distributions. The model randomly picked a value for each individual from these distributions. Finally, we aggregated costs for each item to obtain the net total cost per child. As done by others, we restricted costing to resources consumed during the first year of the study (16;33).

OUTCOMES

The main outcomes were prevalence of anemia (hemoglobin < 100 g/L) at 4 months (end of supplementation), the number of deaths in the first year of study, IQ scores at 5 years of age, and lifetime earnings.

The Simulation Model

The starting point of the model was a data set of 5,000 individuals randomly assigned to Sprinkles or placebo. To create this data set of intercorrelated variables for sociodemographic characteristics, hemoglobin, longitudinal prevalence of diarrhea, febrile child-days and drug usage, we used Monte Carlo simulations using parameter estimates of PSDS. Baseline hemoglobin was not measured in PSDS—

we assumed that the mean hemoglobin was 92 g/L (SD = 10 g/L) in both groups. We compared simulated data of the model with observed data of PSDS for internal validation—simulated data appeared similar to observed data (see Supplementary Table A, which can be viewed online at www.journals.cambridge.org/thc).

After internally validating the model, we followed these individuals for 55 years in a Markov process of time cycles, in which a given set(s) of current values of an individual predicted new values for the same individual in the next time cycle and so on. This model allowed us to examine the effects of intervention, co-interventions and time on outcomes.

Within the Markov process, we used each individual's value for longitudinal prevalence of diarrhea in the current time cycle to predict his/her survival in the next time cycle during the first year of study. Also, we related each individual's hemoglobin concentration at 9 months of age to his/her IQ at 5 years of age. However, we used parameter input for IQ scores from a Pakistani population (24). Next, using parameters from PSDS, and gender and IQ score of each surviving individual, we computed his/her yearly work participation rates (P) and wages (W) from 18–55 years of age. Finally, we computed earnings by taking the product of work participation and wage ($E = P \times W$) (28). We discounted these earnings at a yearly rate of 3 percent to the present monetary value. This was in accordance with the World Bank's recommendation. The complete details of model building and computations are described in a technical appendix, which is available from the authors upon request.

External Validation

For mortality rates, we compared the risk ratio (RR) of the two groups in the model with RR in a recent (unpublished) meta-analysis of randomized clinical trials conducted by R.E. Black (personal communication, 2007), which examined the effect of zinc on mortality by combining data from six trials that used zinc for diarrhea prevention and also reported mortality rates. We considered the model valid, if RR from the model was within the 95 percent confidence interval (CI) of the RR from the meta-analysis. For IQ scores, we compared the mean difference between the two groups in the model with the mean difference in a longitudinal study which reported IQ scores at ages 11–14 years in individuals who were iron deficient in infancy in relation to their counterparts who were not iron deficient, after adjusting for differences in potential confounding factors (gender, maternal IQ, and HOME score) (19). Again, we considered the model valid, if mean difference from the model was within the CI of the mean difference from the longitudinal study—the authors of this study did not report the CI—we estimated it from their reported parameters. For earnings, we did not find any longitudinal study that followed infants stratified by iron status and reported their lifetime earnings—hence, projections on earnings could not be validated.

Economic Analyses

To calculate the incremental benefit of Sprinkles over placebo, first, we calculated the sum of each individual's yearly discounted earnings (discounted lifetime earnings) and the sum of costs incurred on each individual in the first year of the study (total costs). Next, we subtracted the total costs from the discounted lifetime earnings for each individual to obtain the net benefit for each individual. Then, we computed the means of net benefit for the Sprinkles and placebo groups, and took the difference of these means to calculate the incremental benefit.

To quantify uncertainty around these estimates, we performed two kinds of sensitivity analysis: probabilistic sensitivity analysis and scenario analysis (7). The former analysis was to deal with the uncertainty arising from nonvalidated projected difference in lifetime earnings. Thus, we drew 2,000 random samples from the simulated population. Next, we calculated the means of incremental costs and incremental earnings for each sample. Last, we plotted the incremental costs against the incremental earnings, and also calculated the mean incremental benefit for each sample, and estimated the mean and 2.5th and 97.5th percentiles of these means (95 percent probability intervals).

The latter analysis was to deal with the uncertainty arising from variability in effects across populations—less effect in low-risk population and large effect in high-risk population. Thus, we varied the relationship between longitudinal prevalence of diarrhea and mortality, hemoglobin and IQ, and IQ and earnings, by setting the β -coefficients of all rela-

tionships at the lower bounds of their CIs (or ranges) for the low-risk scenario, or at the upper bounds for the high-risk scenario. Specifically, the low-risk scenario assumed that the effect of zinc on diarrhea, and the effect of iron on hemoglobin, would be 10 percent lower than the respective effects in the base case—conversely, the high-risk scenario assumed that the corresponding effects would be 10 percent higher. In addition, the low-risk scenario assumed that the under five mortality rate was 80/1,000 live births, a 5 percent decrease in longitudinal prevalence of diarrhea decreases risk of mortality by 5 percent, a 10 g/L increment in hemoglobin (at 9 months of age) is associated with a 0.38 point rise in IQ (at 5 years of age), and a one-point increment in IQ is associated with a 0.7 percent increment in logarithmically transformed wages. The high-risk scenario assumed that the corresponding values were 150/1,000 live births for under five mortality rate, 23 percent for risk in mortality, 3 points for rise in IQ, and 1.35 percent for logarithmically transformed wages.

For international comparison, we converted both costs and the discounted lifetime earnings calculated in Pakistani rupees to U.S. dollars at the 2003 exchange rate (\$1 = 58.1 Pak rupees), and also to international dollars at the purchasing power parity (PPP) exchange rate of 13.25. We used SAS[®] (version 8.2, SAS institute, Cary, NC) for modeling and analyses.

RESULTS

Costs


Costs are shown in Supplementary Table B, which can be viewed online at www.journals.cambridge.org/thc. The placebo group had no costs for supplementation. However, this saving was offset by higher costs for ORT compared with the Sprinkles group. Net cost per child was \$2.4–\$108 (or \$10.51–\$473.04 international dollars) in the Sprinkles group and \$0.3–\$117 (or \$1.31–\$512.46 international dollars) in the placebo group.

Outcomes

Supplementary Table C, which can be viewed online at www.journals.cambridge.org/thc, shows clinical outcomes from model projections at various time points. The estimated risk ratio for 1 year mortality was 0.82 and the mean difference in IQ scores at 5 years of age was 1.3 points. These are similar to reference values of 0.90 for risk ratio (CI, 0.82 to 0.99) and 1.9 for mean difference in IQ scores (CI, –2.5 to 6.3); the estimates also lie within the respective CIs.

Economic Analyses

Individuals who received Sprinkles in their childhood had higher income during 18 to 55 years of age compared with those who received placebo (Figure 2). Probabilistic sensitivity analysis revealed that most of the data points were in



- Projected earnings of simulated individuals between 18–55 years of age.
- Individuals were intervened in the year 2003 when they were 6–12 month old.
- Individuals joined the workforce in the year 2020 when they were 18 years old.

Figure 2. Projection of undiscounted mean earnings (U.S. dollars).

the right lower quadrant—costs were lower, and earnings were higher in the Sprinkles group compared with placebo (Figure 3). There was 95 percent probability that the mean incremental benefit would be in the interval of \$17 to \$193 (or \$74.54 to \$846.27 international dollars). The present value of incremental benefit of intervening with Sprinkles in childhood was \$106 per child, and varied from \$21 (low-risk scenario) to \$367 (high-risk scenario) (Table 1). In international dollars, this corresponds to \$464.79 (\$92.19 to \$1,611.13).

DISCUSSION


We estimated the clinical and economic effects of home-fortification with micronutrients (including zinc and iron) taking into account the age, gender, and presupplementation longitudinal prevalence of diarrhea and hemoglobin concentrations. When all direct and indirect costs were included, the cost was \$2.4 to \$108 (or \$10.51 to \$473.04

Table 1. Economic Analyses^a

	Mortality Risk ratio	IQ gain	Incremental benefit ^b
Sprinkles versus Placebo			
Base case	0.82	1.3	\$106
Scenario analysis			
Low risk	0.95	0.4	\$21
High risk	0.59	3.0	\$367

^aIn the base case, under five mortality rate (MR) is 125/1,000 live births, a 5% decrease in longitudinal prevalence of diarrhea decreases risk of mortality by 15%, 10 g/L increment in hemoglobin (at 9 months of age) is associated with a 1.75 point rise in IQ (at 5 years of age), and a one-point increment in IQ is associated with a 1.1% increment in wages (log scale). The corresponding values are 80/1,000 live births for MR, 5% for mortality risk, 0.38 points for IQ, and 0.7% for wages, in the low-risk scenario, and 150/1,000 live births, 23%, 3 points and 1.35%, in the high-risk scenario. In addition, the low-risk scenario assumed that the effect of zinc on diarrhea, and the effect of iron on hemoglobin, would be 10% lower than the respective effects in the base case; conversely, the high-risk scenario assumed the corresponding effects to be 10% higher.

^bIncremental benefit = mean net benefit [sprinkles] – mean net benefit [placebo]; where net benefit = earnings – cost.



- Incremental costs represent the mean difference in costs between Sprinkles and placebo groups
- Incremental earnings represent the mean difference in lifetime discounted earnings between Sprinkles and placebo groups
- All values are expressed in US dollars under 95% confidence ellipse

Figure 3. Probabilistic sensitivity analysis.

international dollars) per child in the Sprinkles group and \$0.3 to \$117 (or \$1.31 to 512.46 international dollars) in the placebo group. When long-term effects were modeled, home-fortification was associated with higher lifetime earnings due to reduction in mortality rates and higher IQ scores. The present value of the mean incremental benefit was \$106 (95 percent probability interval = \$17 to \$193), which corresponds to \$464.79 (\$74.54 to \$846.27) international dollars. This means that for each cohort of 10 million at-risk children, reached by a nutritional program, there is a 95 percent chance that the mean incremental benefit from the prevention of earning losses would be in the interval of \$1.7 to \$19.3 billion (or \$7.45 to \$84.62 billion international dollars).

Several studies have demonstrated the efficacy of zinc in treating acute and persistent diarrhea in sick children, and in preventing diarrhea in otherwise healthy children (presumably with zinc deficiency), with subsequent reduction in child mortality. In the treatment setting, all children would receive zinc supplementation. However, in the prevention setting, for efficient use of resources, it is prudent to identify children who may benefit from zinc supplementation. One criterion to

identify such children is recent history of diarrhea (2). PSDS, the study we used to simulate the model population, used this criterion, and thus, was neither purely a treatment trial (intervention in a high-risk population) nor purely a prevention trial (intervention in a low-risk population), but a hybrid of the two (intervention in a moderate risk population). Thus, the current model could project effects for both treatment and prevention settings: RR was 0.59 in the high-risk scenario, which is consistent with results from the pooled analysis of treatment trials (odds ratio, 0.58; CI, 0.37 to 0.90) (6); and RR was 0.95 in the low-risk scenario which is consistent with results from Black’s meta-analysis of prevention trials (RR, 0.90; CI, 0.82 to 0.99) (personal communication, 2007). The projected 18 percent reduction (RR, 0.82) in the moderate risk population rightly tends toward the lower bound of CI from prevention studies, but tends toward the upper bound of CI from treatment studies. Hence, the model projections on mortality appear valid.

There is ample evidence that iron plays a role in brain development and that iron deficiency during infancy (a crucial period of development) may irreversibly impair cognitive development (20). This is further supported by observations

of Palti and colleagues (23), who followed a cohort from infancy to 5 years of age. IQ scores at 5 years of age were significantly higher for children who had higher hemoglobin concentrations at 9 months of age compared with their peers who had lower hemoglobin concentrations at the same age. Each 10 g/L increment in hemoglobin was associated with a 1.75-point rise in IQ after controlling for other factors such as parent education and schooling. They concluded that iron has a role in cognitive development. In Chile, Rivera and Walter (25) performed IQ testing at age 10 years in a subset of their original cohort which was tested for iron deficiency in infancy, and so did Lozoff and colleagues (19) in Costa Rica at age 11–14 years; in both studies on average IQ scores were approximately 5 points higher in individuals who were not iron deficient in infancy. Lozoff and colleagues adjusted the mean difference for gender, maternal IQ, and HOME score—there was a 1.9-points gain in IQ scores which was nonsignificant (most likely due to lack of power). Our projected gain of 1.3 IQ points is similar to this estimate; in scenario analyses, our estimates ranged from 0.48 IQ points (low risk) to 3.0 IQ points (high risk), which appear conservative, compared with the observed 5 IQ points difference in Chile and Cost Rica.

A moderate correlation between IQ and earnings ($r = 0.4\text{--}0.6$) has been observed in several studies across various countries, including Pakistan; (13) Alderman and colleagues (1) used regression models to estimate the effect of cognitive scores on wages using data from rural Pakistan. The dependent variable in their models was logarithm of wages. Beta coefficient ranged from 0.007 to 0.017, which means that each point increment in cognitive score was associated with 0.7 percent to 1.7 percent increment in log-transformed wages. They concluded that a one standard deviation increase in cognitive achievement suggests an increase in wages of over 20 percent. Therefore, our projected impact on wages and earnings is plausible.

Our results are not directly comparable to previous economic evaluations of iron interventions. We modeled the combined effect of zinc and iron on mortality and cognitive development using computer simulations. Thus, our results are not comparable to Baltussen and colleagues (3), who restricted their analyses of cost-effectiveness of iron interventions to mortality in pregnant women, and did not model the effects of iron on cognitive development in children. Similarly, our results are not comparable to those of Horton and Ross (13), who did not model the effect of an iron intervention, but rather the economic consequences of iron deficiency. After a literature review, they conservatively deduced that a decrease in one-half standard deviation on cognitive scores is associated with a 4 percent drop in hourly wages for adults (or say one point decrement in cognitive score is associated with 0.53–0.8 percent drop in hourly wages). They assumed an average inter-correlation of 0.62 between IQ scores of childhood and adulthood, and assumed that childhood anemia is associated with a 2.5 percent drop in wages in adulthood ($4 \times$

0.62). From further extrapolation, they estimated a median 5 percent of GDP per capita loss for Pakistan (including both sexes) due to childhood anemia. However, despite different analytic framework, we arrived at similar conclusions as those of Baltussen et al., and Horton and Ross—iron interventions are cost effective, and iron deficiency has economic consequences.

The idea of capturing cognitive effects on work productivity is inspired by Schwartz's work (28) which examined the effect of lead toxicity in the United States; high blood lead levels were associated with lower IQ, and lower IQ scores were associated with lower work participation rates and earnings. Following this, Salkever (26) used data from the National Longitudinal Survey of Youth (NLSY), and estimated that each additional IQ point raises probability of work participation by 0.16 percent in males and 0.36 percent in females. Using linear regression fitted by least squares, he reported an independent effect of IQ on earnings after controlling for schooling, gender, parent education and race. This effect combines the effects of IQ on work participation and wages (from his data, we estimate that for each one point IQ rise, wages increase by 1.1 percent, which is similar to what Alderman et al. reported) (1). This was further examined by Grosse and colleagues (10), who used data from the National Health and Nutrition Examination Surveys (NHANES), and estimated that each IQ point raises worker's productivity in the range of 1.76–2.38 percent. Recently, Trasande and colleagues (35) have used the same model to estimate economic burden from mercury toxicity. We have applied this approach in the context of iron deficiency in a developing country after accounting for local work participation and wage rates.

Our results should be used in the context of study limitations. Our model applies to children in developing countries who are at risk of premature mortality and impaired cognitive development because of zinc and iron deficiencies, and who may benefit the most from home-fortification; the benefits would be less in low-risk populations compared with high-risk populations. Thus, the results are not generalizable to the well-off segments of the population who do not have zinc and iron deficiencies, and thus, may not benefit from zinc and iron supplementation. Having acknowledged that, our results are generalizable to millions of children throughout the world who live in poverty (36). Other limitations included lack of direct observations from a Sprinkles intervention to support effect on mortality, IQ, and earnings. However, in Sprinkles, zinc (5 mg and 10 mg) and iron (30 mg and 45 mg) are bioavailable and are effective against diarrhea and iron deficiency anemia, respectively. Thus, there is sufficient biological and epidemiological evidence to support causal effects on mortality and IQ from this intervention. Furthermore, despite of indirectly modeling the effect of zinc on mortality (through the effect of zinc on diarrhea and the effect of diarrhea on mortality), and indirectly modeling the effect of iron on IQ (through the effect of iron on hemoglobin and the effect of hemoglobin on IQ), our results

are in agreement with findings from previous studies. This attests to the validity of our results. Although, the effect on earnings could not be validated, sensitivity analyses revealed that upon varying the parameter values, our conclusions did not change—home-fortification is cost-effective. Thus, we believe that our conclusions are not adversely affected by the limitations in the current study.

POLICY IMPLICATIONS

In conclusion, home-fortification using Sprinkles is a cost-effective approach to combat common nutritional deficiencies and that it has long-lasting benefits that far outweigh its costs. Sprinkles have already been incorporated into the Lady Health Workers' program in Pakistan on a nationwide scale (14). Nevertheless, our results are applicable for evidence-based decision making in other developing countries, where collectively, 7–85 billion international dollars per 10 million at-risk children could be saved by preventing premature mortality and impaired cognitive development.

CONTACT INFORMATION

Waseem Sharieff, MD, PhD (doc.sharieff@utoronto.ca), Adjunct Faculty, Department of Health Policy, Management and Evaluation, University of Toronto, 155 College Street, Suite 425, Toronto, Ontario M5T 3M6, Canada; Resident Physician, Department of Postgraduate Medicine, Radiation, Oncology Program, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4L8, Canada

Stanley H. Zlotkin, MD, PhD (Stanley.zlotkin@sickkids.ca), Professor, Department of Public Health Science, University of Toronto, 155 College Street, Toronto, Ontario, Canada, M5T 3M6; Senior Scientist, Program in Child Health and Evaluative Sciences, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada

Wendy J. Ungar, PhD (wendy.ungar@sickkids.ca), Associate Professor, Departments of Health Policy, Management & Evaluation, University of Toronto, 155 College Street, Suite 425, Toronto, Ontario M5T 3M6, Canada; Senior Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada

Brian Feldman, MD, MSc (brian.feldman@sickkids.ca), Associate Professor, Department of Health Policy, Management, and Evaluation, University of Toronto, 155 College Street, Toronto, Ontario M5T 3M6, Canada; Rheumatologist, Division of Rheumatology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1XB, Canada

Murray D. Krahn, MD, MSc (murray.krahn@theta.utoronto.ca), Associate Professor, Health Policy, Management & Evaluation, University of Toronto, 155 College Street, Suite 425, Toronto, Ontario M5T 3M6, Canada; Senior Scientist, Division of Clinical Decision-Making &

Health Care, Toronto General Research Institute, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada

George Tomlinson, PhD (george.tomlinson@utoronto.ca), Assistant Professor, Public Health Sciences, University of Toronto, 6th Floor, 155 College Street, Health Sciences Building, Toronto, Ontario M5T 3M7, Canada; Scientist, Department of Medicine, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada

REFERENCES

1. Alderman H, Behrman J, Ross D, et al. The returns to endogenous human capital in Pakistan's rural wage labour market. *Oxford Bull Econ Stat.* 1996;58:29-55.
2. Bairagi R, Koenig MA, Mazumder KA. Mortality-discriminating power of some nutritional, sociodemographic, and diarrheal disease indices. *Am J Epidemiol.* 1993;138:310-317.
3. Baltussen R, Knai C, Sharan M. Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world. *J Nutr.* 2004;134:2678-2684.
4. Bern C, Martines J, de Zoysa I, et al. The magnitude of the global problem of diarrhoeal disease: A ten-year update. *Bull World Health Organ.* 1992;70:705-714.
5. Bhutta ZA, Bird SM, Black RE, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: Pooled analysis of randomized controlled trials. *Am J Clin Nutr.* 2000;72:1516-1522.
6. Bhutta ZA, Jiwani A, Feroze A, et al. *Assessment of human zinc deficiency and determinants in Pakistan: Implications for interventions.* www.fertilizer.org/ifa/publicat/PDF/2007_zincrops2007_bhutta.pdf. Accessed 5 October 2007.
7. Briggs A. Handling uncertainty in economic evaluation. *BMJ.* 1999;319:120.
8. Campbell F, Pungello E, Miller-Johnson S, et al. The development of cognitive and academic abilities: Growth curves from an early childhood educational experiment. *Dev Psychol.* 2001;37:231-242.
9. Economic Indicators—Pakistan, 2004. http://earthtrends.wri.org/pdf_library/country_profiles/Eco_cou_586.pdf. Accessed 15 December 2004.
10. Grosse S, Matte T, Schwartz J, et al. Economic gains resulting from the reduction in children's exposure to lead in the United States. *Environ Health Perspect.* 2002;110:563-569.
11. Henry F. The epidemiologic importance of dysentery in communities. *Rev Infect Dis.* 1991;13:S238-S244.
12. Hodgson TA. The state of the art of cost-of-illness estimates. *Adv Health Econ Health Serv Res.* 1983;4:129-164.
13. Horton S, Ross J. The economics of iron deficiency. *Food Policy.* 2003;28:51-75.
14. Krivel P. A spoonful of 'Sprinkles' helps the medicine go down. *The Toronto Star.* 3 June 2004. http://www.thestar.com/NASA/pp/cs/ContentServer?pagename=thestar/Layout/Article_Type1&call_pageid=971358637177&c=Article&cid=1086086012442. Accessed 16 June 2004.
15. Layard R, Glaister S. *Cost benefit analysis.* Cambridge: Cambridge University Press; 1994.

16. Loevinsohn BP, Sutter RW, Costales MO. Using cost-effectiveness analysis to evaluate targeting strategies: The case of vitamin A supplementation. *Health Policy Plan.* 1997;12:29-37.
17. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. *Lancet.* 2006;367:1747-1757.
18. Lozoff B, Beard J, Connor J, et al. Long-lasting neural and behavioral effects of iron deficiency in infancy. *Nutr Rev.* 2006;64(pt 2):S34-S43.
19. Lozoff B, Jimenez E, Hagen J, et al. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. *Pediatrics.* 2000;105:E51.
20. Lozoff B. Behavioral alterations in iron deficiency. *Adv Pediatr.* 1988;35:331-359.
21. Molla A, Kharshed M, Molla AM. Prevalence of iron deficiency anaemia in children of the urban slums of Karachi. *J Pak Med Assoc.* 1992;42:118-121.
22. Morris S, Cousens S, Kirkwood B, et al. Is prevalence of diarrhea a better predictor of subsequent mortality and weight gain than diarrhea incidence? *Am J Epidemiol.* 1996;144:582-588.
23. Palti H, Pevsner B, Adler B. Does anemia in infancy effect achievement on development and intelligence tests? *Human Biol.* 1983;55:194-198.
24. Rahman A, Maqbool E, Zuberi HS. Lead-associated deficits in stature, mental ability and behaviour in children in Karachi. *Ann Trop Paediatr.* 2002;22:301-311.
25. Rivera F, Walter T. Effects on school performance at age ten years of former iron deficiency anemia in infancy. *Rev Child Pediatr.* 1996;67:141-147.
26. Salkever D. Updated estimates of earnings benefits from reduced exposure of children to environmental lead. *Environ Res.* 1995;70:1-6.
27. Schauer C, Zlotkin S. Home fortification with micronutrient sprinkles—A new approach for the prevention and treatment of nutritional anemias. *Paediatr Child Health.* 2003;8:87-90.
28. Schwartz J. Societal benefits of reducing lead exposure. *Environ Res.* 1994;66:105-24.
29. Shankar A, Prasad A. Zinc and immune function: The biologic basis of altered resistance to infection. *Am J Clin Nutr.* 1998;68:447S-463S.
30. Sharieff W, Bhutta ZA, Schauer C, et al. Micronutrients (including zinc) reduce diarrhoea in children: The Pakistan sprinkles diarrhoea study. *Arch Dis Child.* 2006;91:573-579.
31. Sharieff W, Horton SE, Zlotkin S. Economic gains of a home fortification program: Evaluation of “Sprinkles” from the provider’s perspective. *Can J Public Health.* 2006;97:20-23.
32. Sharieff W, Zlotkin S, Tondeur M, et al. Physiologic mechanisms can predict hematologic responses to iron supplements in growing children: A computer simulation model. *Am J Clin Nutr.* 2006;83:681-687.
33. Sweat M, Gregorich S, Sangiwa G, et al. Cost effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. *Lancet.* 2000;356:113-121.
34. Tondeur MC, Schauer CS, Christofides AL, et al. Determination of iron absorption from intrinsically labeled microencapsulated ferrous fumarate (sprinkles) in infants with different iron and hematologic status by using a dual-stable-isotope method. *Am J Clin Nutr.* 2004;80:1436-1444.
35. Trasande L, Landrigan PJ, Schechter C. Public health and economic consequences of methyl mercury toxicity to the developing brain. *Environ Health Perspect.* 2005;113:590-596.
36. United Nations Children’s Education Fund. *The state of the world’s children 2005: “Childhood under threat.”* <http://www.unicef.org/sowc05/english/fullreport.html>. Accessed 12 July 2005.
37. Walter T. Effect of iron-deficiency anemia on cognitive skills and neuromaturation in infancy and childhood. *Food Nutr Bull.* 2003;24(Suppl):S104-S110.
38. Yoon P, Black R, Moulton L, et al. The effect of malnutrition on the risk of diarrheal and respiratory mortality in children <2 y of age in Cebu, Philippines. *Am J Clin Nutr.* 1997;65:1070-1077.
39. Zlotkin SH, Schauer C, Agyei SO, et al. Demonstrating zinc and iron bioavailability from intrinsically labeled microencapsulated ferrous fumarate and zinc gluconate sprinkles in young children. *J Nutr.* 2006;136:92092-92095.
40. Zlotkin SH, Schauer C, Christofides A, et al. Micronutrient sprinkles to control childhood anaemia. *PLoS Med.* 2005;2:e1.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.